Tyra Biosciences (NASDAQ:TYRA) Stock Price Down 4.7% – What’s Next?

Tyra Biosciences, Inc. (NASDAQ:TYRA)’s stock price traded down 4.7% during mid-day trading on Monday . The company traded as low as $11.11 and last traded at $10.96. 29,593 shares changed hands during mid-day trading, a decline of 90% from the average session volume of 293,406 shares. The stock had previously closed at $11.50.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. UBS Group started coverage on shares of Tyra Biosciences in a report on Tuesday, January 7th. They set a “buy” rating and a $28.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 target price on shares of Tyra Biosciences in a research note on Tuesday, February 18th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $30.50.

Tyra Biosciences Trading Down 5.3 %

The stock’s 50 day moving average price is $13.55 and its 200 day moving average price is $17.08. The firm has a market cap of $550.81 million, a PE ratio of -6.76 and a beta of 1.09.

Insider Activity at Tyra Biosciences

In related news, Director Nina S. Kjellson sold 7,779 shares of the firm’s stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $16.29, for a total transaction of $126,719.91. Following the transaction, the director now directly owns 447,857 shares in the company, valued at $7,295,590.53. This trade represents a 1.71 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last 90 days, insiders sold 21,998 shares of company stock valued at $344,818. Insiders own 15.40% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. KLP Kapitalforvaltning AS acquired a new position in shares of Tyra Biosciences during the fourth quarter valued at $31,000. US Bancorp DE acquired a new position in Tyra Biosciences during the 4th quarter valued at about $50,000. BNP Paribas Financial Markets bought a new position in Tyra Biosciences in the 4th quarter worth about $60,000. Aquatic Capital Management LLC bought a new stake in shares of Tyra Biosciences during the fourth quarter valued at approximately $64,000. Finally, Wells Fargo & Company MN boosted its position in shares of Tyra Biosciences by 51.7% during the fourth quarter. Wells Fargo & Company MN now owns 9,493 shares of the company’s stock worth $132,000 after buying an additional 3,236 shares during the period. 84.14% of the stock is currently owned by institutional investors.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.